By detecting the expression of kinases at the gene level in the PI3K/HDAC pathways with the CCLE database, we found that the expression levels of ErbB2 and ErbB3 in hematologic tumor cells were lower than those in solid tumors. This evidence concerns the gene ERBB3 and hematopoietic and lymphoid cell neoplasm.